EC
RVMD icon

Euclidean Capital’s Revolution Medicines RVMD Stock Holding History

Euclidean Capital’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-93,436
Closed -$3.7M – 14
2020
Q4 		$3.7M Buy
+93,436
New +$3.69M 0.78% 9

Other funds holding RVMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

Euclidean Capital's RVMD Position: Q1 2021 in Review

Euclidean Capital sold out of Revolution Medicines (RVMD) in Q1 2021, closing a stake of 93,436 shares — an estimated $3.7M sold.

Euclidean Capital first reported a position in RVMD in Q4 2020 and held it in 1 quarter. The position peaked at $3.7M in Q4 2020. 128 funds tracked by Wall St. Rank hold RVMD as of Q1 2021.

  • Euclidean Capital reported no remaining Revolution Medicines position as of Q1 2021 after selling out during the quarter.
  • Euclidean Capital sold 93,436 Revolution Medicines shares in Q1 2021, an estimated $3.7M.
  • Euclidean Capital first reported a position in Revolution Medicines in Q4 2020 and held it in 1 quarter.
  • Euclidean Capital's Revolution Medicines position peaked at $3.7M in Q4 2020.
  • 128 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2021.

Based on Euclidean Capital's 13F filing for Q1 2021, filed 17 May 2021.